
Safety Considerations and Treatment Selection for CELMoDs in Relapsed/Refractory Multiple Myeloma
Faculty discuss safety considerations across CELMoD-based regimens, including neutropenia, infections, and thromboembolic risk.
Episodes in this series

Faculty discuss safety considerations across CELMoD-based regimens, including neutropenia, infections, and thromboembolic risk. They emphasize proactive management with growth factor support, dose modifications, infection prevention, and appropriate thromboprophylaxis. Although neutropenia appears to be a shared toxicity, its severity and associated risks may vary across regimens. The discussion then shifts to selecting between iberdomide- and mezigdomide-based combinations, highlighting differences in trial populations, prior CD38 exposure, disease characteristics, and treatment intensity. Faculty consider daratumumab-based therapy for selected patients with a less aggressive relapse pattern, while a carfilzomib-based combination may be appropriate for patients relapsing on CD38-directed therapy or requiring a more intensive approach. They also discuss the importance of evaluating each patient’s ability to tolerate treatment and the limitations of available evidence, particularly regarding mezigdomide activity after prior iberdomide exposure. Faculty emphasize that treatment selection should be individualized rather than based on indirect comparisons between trials.
Related to this article








